A phase II study of selinexor(KPT-330) combined with bortezomib and dexamethasone (SVD) for induction and consolidation for patients with progressive or refractory multiple myeloma: The selvedex trial

Autor: Broijl, A, Asselbergs, E L, Minnema, M C, Lonergan, S, van der Holt, B, van de Donk, N, Zweegman, S, Sonneveld, P

Publikováno v: Broijl, A, Asselbergs, E L, Minnema, M C, Lonergan, S, van der Holt, B, van de Donk, N, Zweegman, S & Sonneveld, P 2018, A phase II study of selinexor(KPT-330) combined with bortezomib and dexamethasone (SVD) for induction and consolidation for patients with progressive or refractory multiple myeloma: The selvedex trial . Congr Eur Hematol Assoc (EHA) SO-Congr Eur Hematol Assoc (EHA) . < http://www.mendeley.com/research/phase-ii-study-selinexorkpt330-combined-bortezomib-dexamethasone-svd-induction-consolidation-patient >

Selinexor is an oral selective exportin-1 (XPO-1) inhibitor that forces nuclear retention and activation of many tumor suppressor proteins (TSPs) and IkB and is active as monotherapy and combined with dexamethasone in multiple myeloma (MM). Addition

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::a5308385c079a85e3e9d44d088326f54
https://research.vumc.nl/en/publications/013807f3-261c-4af9-a6b7-7ddd7d6050c6